Skye Bioscience Inc. (SKYE)
NASDAQ: SKYE
· Real-Time Price · USD
3.86
0.26 (7.22%)
At close: Sep 26, 2025, 10:59 AM
7.22% (1D)
Bid | 2.73 |
Market Cap | 119.71M |
Revenue (ttm) | n/a |
Net Income (ttm) | -42.37M |
EPS (ttm) | -1.06 |
PE Ratio (ttm) | -3.64 |
Forward PE | -2.73 |
Analyst | Buy |
Dividends | n/a |
Ask | 4.51 |
Volume | 158,591 |
Avg. Volume (20D) | 552,661 |
Open | 3.60 |
Previous Close | 3.60 |
Day's Range | 3.50 - 3.86 |
52-Week Range | 1.14 - 5.96 |
Beta | 2.34 |
Ex-Dividend Date | n/a |
About SKYE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SKYE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SKYE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+32.87%
Skye Bioscience shares are trading higher after th...
Unlock content with
Pro Subscription
4 months ago
+14.97%
Skye Bioscience shares are trading higher after the company announced a collaboration with Arecor to improve dosing and patient compliance.

2 months ago · seekingalpha.com
Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab DosingSkye Bioscience's Nimacimab remains a promising peripheral CB1 antibody for obesity with lean-mass preservation and fewer GI issues. Nimacimab's Phase 2a topline is expected by Q3-Q4 2025, which is it...